Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases
The Prostate, 06/21/2012
Todenhofer T et al. – The results of the study indicate that localized prostate cancer (PC) is associated with early specific changes of the receptor activator of the NF–kB ligand (RANKL) pathway in serum and bone marrow. These changes might be part of the pre–metastatic niche of PC and implicate a potential benefit of RANKL inhibition in patients with localized PC.